Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06714825Phase 1Completed

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

Role: lead

NCT06581159Phase 1Terminated

Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Role: lead

NCT07143448Phase 1Not Yet Recruiting

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

Role: lead

NCT07123779Phase 1Not Yet Recruiting

Study of HS235 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

Role: lead

NCT06493461Phase 1Terminated

A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults

Role: lead

All 5 trials loaded